Australia markets closed
  • ALL ORDS

    7,239.40
    +30.40 (+0.42%)
     
  • ASX 200

    7,014.20
    +31.50 (+0.45%)
     
  • AUD/USD

    0.7785
    +0.0055 (+0.71%)
     
  • OIL

    65.51
    +1.69 (+2.65%)
     
  • GOLD

    1,844.00
    +20.00 (+1.10%)
     
  • BTC-AUD

    61,279.40
    -4,259.38 (-6.50%)
     
  • CMC Crypto 200

    1,398.33
    +39.77 (+2.93%)
     
  • AUD/EUR

    0.6405
    +0.0011 (+0.17%)
     
  • AUD/NZD

    1.0724
    -0.0028 (-0.26%)
     
  • NZX 50

    12,367.86
    -60.26 (-0.48%)
     
  • NASDAQ

    13,393.12
    +283.97 (+2.17%)
     
  • FTSE

    7,043.61
    +80.28 (+1.15%)
     
  • Dow Jones

    34,382.13
    +360.68 (+1.06%)
     
  • DAX

    15,416.64
    +216.96 (+1.43%)
     
  • Hang Seng

    28,027.57
    +308.90 (+1.11%)
     
  • NIKKEI 225

    28,084.47
    +636.46 (+2.32%)
     

Mental Disorder Drugs Market Report 2021-2031

ReportLinker
·5-min read

Forecasts by Drug Class (SSRIs, SNRIs, Atypical, Antipsychotics, TCAs, SARIs, Benzodiazepines, MAOIs, Others), by Indication (Depression, Schizophrenia, Bipolar Disorder, Post-traumatic, Stress Disorder, Others), by End-user (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy) AND Regional and Leading National Market Analysis PLUS Analysis of Leading Mental Disorder Drugs Companies AND COVID-19 Recovery Scenarios

New York, April 15, 2021 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Mental Disorder Drugs Market Report 2021-2031" - https://www.reportlinker.com/p06061830/?utm_source=GNW


Mental Disorder Drugs Market - reveals latest trends, opportunities, predicted revenues, and competitive analysis. Read on to determine how you can exploit the impending business opportunities emerging in this sector along with detailed COVID-19 recovery scenarios.
Global mental disorder drugs market is projected to reach at a market value of US$xx billion by 2031 with a lucrative CAGR during the forecast period. The growing prevalence of mental disorders including depression, bipolar disorder, anxiety, and schizophrenia is a major factor that drives the demand for mental disorder drugs. Other key drivers boosting the market growth are growing mental health awareness in developing countries; adoption of mental disorder drugs for treatment & maintenance therapy; and rising R&D investment by the leading pharmaceutical companies in the area of mental health. In addition, the COVID-19 pandemic has a significant impact on the mental disorder drugs market. The COVID-19 pandemic has resulted in a growing incidence of mental disorders due to unemployment, financial crisis, health issues, and stress. Thus, the demand for mental disorder drugs is expected to rise during the forecast period.
This report shows you the potential revenues streams to 2031, assessing the different segments, major players, qualitative analysis, opportunities trends, and business prospects in the mental disorder drugs industry.
To access the data contained in this document please email contactus@visiongain.com

How this report will benefit you
This new study is envisioned for anyone requiring commercial in-depth analyses for the global mental disorder drugs market along with detailed segment analysis in the market. Our new study assists you to evaluate the overall global and regional market for mental disorder drugs. Get the financial analysis of the overall market and different segments including by drug class, route of administration, usability, and distribution channel. High opportunity remains in this fast-growing mental disorder drugs market. See how to use the existing and upcoming opportunities in this market to gain revenue benefit in the near future. Moreover, the report would help you to improve your strategic decision making, allows you to frame growth strategies, reinforce the analysis of other market players, and maximise productivity of the company.
Forecasts to 2031 and other analyses reveal the commercial prospects
. Our new study provides you with revenue forecast by different segments including drug class, indication, and distribution channel to 2031
. It also includes growth rates for different 5 regional markets along with 18 countries and COVID-19 impact analysis on each market
. The profiles of the top 15 companies are very descriptive and comprehensive data including company snapshot, overview, commercial developments, company market shares, and detailed financial analysis with revenue and other financials
. The COVID-19 has a positive impact on the mental disorder drugs industry and the report includes detailed analysis and invaluable insight into how COVID-19 will affect the industry.
Discover sales forecasts for the global and regional market forecasts from 2021-2031
Along with revenue prediction for the overall global market, there is segmentation by region for 5 regional markets including North America, Europe, Asia Pacific, Latin America, and MEA and 20 major countries.
Global Mental Disorder Drugs Market Revenue and Growth Forecasts from 2021 to 2031 By Drug Class
. SSRIs
. SNRIs
. Atypical Antipsychotics
. TCAs
. SARIs
. Benzodiazepines
. MAOIs
. Others
Global Mental Disorder Drugs Market Revenue and Growth Forecasts from 2021 to 2031 By Indication
. Depression
. Schizophrenia
. Bipolar disorder
. Post-traumatic Stress Disorder
. Others
Global Mental Disorder Drugs Market Revenue and Growth Forecasts from 2021 to 2031 By Distribution Channel
. Hospital Pharmacy
. Retail Pharmacy
. Others

Regional market revenue and growth forecasts from 2021 to 2031:
. North America
- U.S.
- Canada
. Europe
- Germany
- UK
- France
- Italy
- Spain
- Russia
- Rest of Europe
. Asia Pacific
- Japan
- China
- India
- Australia
- South Korea
- Rest of Asia Pacific
. Latin America
- Brazil
- Mexico
- Argentina
- Rest of Latin America
. Middle East and Africa
- South Africa
- Saudi Arabia
- Rest of MEA

Need industry data? Please contact us today.
Detailed profiles of 15 leading companies that are operating in the market
The report includes profiles of 15 major companies involved in the mental disorder drugs market. The companies profiled in this report include: AbbVie, AstraZeneca, Bausch Health, Bristol-Myers Squibb, Eli Lilly and Company, GlaxoSmithKline, H. Lundbeck, Johnson & Johnson, Mallinckrodt Pharmaceuticals, Merck, Novartis, Otsuka Pharmaceutical, Pfizer, Takeda Pharmaceutical, and Teva Pharmaceutical Industries.
Find qualitative and quantitative analyses with independent predictions. Receive information that only our report contains, staying informed with this invaluable business intelligence.

In summary, our 429-page report delivers you with the following knowledge:
. Revenue forecasts from 2021 to 2031 for the global mental disorder drugs market and subsegments (by drug class, indication, distribution channel, and region)- discover the industry’s prospects, finding the most lucrative areas for investments and revenue generation
. Detailed profiles of top 15 mental disorder drugs manufacturers, with financial overviews for net revenues, operating income, R&D investment, and segment revenues
. Revenue forecasts from 2021 to 2031 for 5 regional markets - See forecasts for the mental disorder drugs market in North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa.

Read the full report: https://www.reportlinker.com/p06061830/?utm_source=GNW

About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________

CONTACT: Clare: clare@reportlinker.com US: (339)-368-6001 Intl: +1 339-368-6001